Arylomycin Analogs Overcoming Bacterial Resistance
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Bacterial infections resistant to arylomycin treatment require new chemical compounds that can effectively target and treat these resistant strains.
Innovation Solution
Development of arylomycin analogs with specific structural modifications, including various alkyl, alkenyl, cycloalkyl, heterocyclyl, and aryl groups, to enhance antibacterial activity against resistant bacterial infections.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If natural arylomycin is used for treatment, then antibacterial activity is achieved, but bacterial resistance develops
Solution Approach 1:
The patent applies parameter changes by systematically modifying the chemical structure of arylomycin at multiple positions (R1, R2, R3, R5, and acyl tail variations) to create analogs with altered properties that maintain antibacterial activity while overcoming resistance mechanisms developed against the natural product
Solution Approach 2:
The patent creates composite chemical structures by combining the core arylomycin scaffold with various substituent groups (halogens, alkyl chains, heterocycles, aromatic rings) to produce a series of analogs with enhanced and diversified antibacterial profiles against resistant strains
2Reliability
If arylomycin analogs with structural modifications are developed, then effectiveness against resistant strains is improved, but chemical complexity increases
Solution Approach 1:
The patent segments the arylomycin molecule into distinct modifiable regions (N-terminal acyl tails, positions R1-R5 on the core structure) that can be independently varied to optimize antibacterial activity against resistant strains while maintaining the essential pharmacophore
Solution Approach 2:
The patent applies local quality by introducing specific substituent groups at particular positions on the arylomycin core structure (such as halogens at R2/R3, aromatic groups at R5) to enhance activity against resistant bacteria while keeping the overall molecular framework recognizable and functional
Data Source
AI summary
Provided herein are analogs of the natural product arylomycin for the treatment of microbial infections. In some embodiments, the compounds described herein have broad spectrum bioactivity. The compounds provided herein can in other embodiments overcome the resistance conferred by single amino acid mutations at defined positions of bacterial Signal Peptidases (SPases) and in other embodiments provide for a broader spectrum of antibiotic bioactivity compared to the natural product. Pharmaceutical compositions and methods for treatment using the compounds described herein are also provided.